Literature DB >> 8453612

Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice.

I Ahmad1, M Longenecker, J Samuel, T M Allen.   

Abstract

Cancer chemotherapy is limited by adverse side effects resulting from toxicities to normal tissues. Targeted delivery of drugs to diseased tissues in vivo would help to reduce these side effects. Liposomes containing lipid derivatives of polyethylene glycol have circulation times sufficiently long to allow for effective in vivo drug delivery. Polyethylene glycol liposomes, containing entrapped doxorubicin, targeted to KLN-205 squamous cell carcinoma of the lung by means of specific antibodies attached at the liposome surface were capable of reducing tumor burden to a high degree and eradicating tumor in a significant percentage of mice.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8453612

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells.

Authors:  A W El-Kareh; T W Secomb
Journal:  Neoplasia       Date:  2000 Jul-Aug       Impact factor: 5.715

2.  Receptor-specific targeting with liposomes in vitro based on sterol-PEG(1300) anchors.

Authors:  Markus Gantert; Felicitas Lewrick; Joanna E Adrian; Jochen Rössler; Thomas Steenpass; Rolf Schubert; Regine Peschka-Süss
Journal:  Pharm Res       Date:  2008-11-18       Impact factor: 4.200

Review 3.  Gene therapy for cancer--in the dock, blown off course or full speed ahead?

Authors:  R C Vile
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

4.  Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.

Authors:  K B Quattrocchi; C H Miller; S Cush; S A Bernard; S T Dull; M Smith; S Gudeman; M A Varia
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

5.  Development of anti-p185HER2 immunoliposomes for cancer therapy.

Authors:  J W Park; K Hong; P Carter; H Asgari; L Y Guo; G A Keller; C Wirth; R Shalaby; C Kotts; W I Wood
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

6.  Structure and phase behavior of lipid suspensions containing phospholipids with covalently attached poly(ethylene glycol).

Authors:  A K Kenworthy; S A Simon; T J McIntosh
Journal:  Biophys J       Date:  1995-05       Impact factor: 4.033

Review 7.  Gene therapy for PNET.

Authors:  C Raffel
Journal:  J Neurooncol       Date:  1996-07       Impact factor: 4.130

8.  A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma.

Authors:  Ximin Chen; Guipeng Ding; Qihe Gao; Jian Sun; Qianqian Zhang; Lijian Du; Zhenning Qiu; Changjun Wang; Feng Zheng; Bowang Sun; Jian Ni; Zhenqing Feng; Jin Zhu
Journal:  PLoS One       Date:  2013-05-13       Impact factor: 3.240

Review 9.  Anthracyclines in the treatment of cancer. An overview.

Authors:  G N Hortobágyi
Journal:  Drugs       Date:  1997       Impact factor: 9.546

10.  A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo.

Authors:  S A Longman; P R Cullis; L Choi; G de Jong; M B Bally
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.